Sun Pharmaceuticals Industries Ltd

(SUNPHARMA)

Sun Pharma and Alkem Respond to Drug Quality Alerts - 15 Nov, 2024

Sun Pharmaceuticals and Alkem Laboratories have clarified that they did not manufacture drugs labeled as NSQ or spurious, following a regulatory alert that could impact their reputations and finances due to misinformation.

Sun Pharma's Strong Global Presence and Financial Growth - 13 Nov, 2024

Sun Pharmaceuticals, India's largest pharma company, boasts a diverse portfolio and significant US market revenue. With robust growth projections and a strong dollar benefiting exports, the company is well-positioned for continued success.

Sun Pharma Faces Delays and Declining Sales - 05 Nov, 2024

Sun Pharma reported a significant decline in net sales and increased losses for September 2024. Additionally, the launch of its alopecia drug Leqselvi is delayed due to legal issues.

Sun Pharma Faces Setback with Leqselvi Launch Delay - 04 Nov, 2024

Sun Pharma's planned launch of Leqselvi is delayed due to a US court injunction over patent infringement. The ruling could significantly impact projected sales and investor sentiment, leading to a 5% drop in stock price. The company plans to appeal and explore settlement options with Incyte Corporation.

Sun Pharma Faces Delay in Leqselvi Launch - 03 Nov, 2024

Sun Pharmaceuticals faces a setback as a US court issues a preliminary injunction delaying the launch of its drug Leqselvi. The company plans to appeal the decision. Despite this, Sun Pharma reported strong quarterly financial results, with a net profit increase of 27.94% year-on-year.

Sun Pharma's Leqselvi Launch Blocked by Court - 02 Nov, 2024

Sun Pharmaceuticals faces a setback as the US District Court grants a preliminary injunction preventing the launch of its new drug, Leqselvi, pending legal developments. The company plans to appeal the decision.

Analysts Bullish on Sun Pharma's Growth Prospects - 30 Oct, 2024

Motilal Oswal Financial Services has reiterated a buy rating on Sun Pharmaceutical Industries, setting a target price of Rs 2,280, highlighting growth in specialty products and effective cost control. KR Choksey also raised the target price to Rs 1,967, reflecting confidence in the company's US specialty business and market leadership in India.

Sun Pharma Reports Strong Q2 Growth and Profit - 29 Oct, 2024

Sun Pharmaceuticals Industries Ltd achieved a 28% year-on-year increase in net profit for Q2 FY25, driven by robust sales in domestic and specialty portfolios. Revenue rose 10.5%, and EBITDA surged 23.9%. Analysts maintain a positive outlook, with target prices ranging from ₹1,600 to ₹2,264, reflecting strong performance despite some concerns over R&D spending and market conditions.

Sun Pharma Reports Strong Q2 Earnings Performance - 28 Oct, 2024

Sun Pharmaceuticals Industries Ltd announced a robust Q2FY25 with a 28% increase in net profit to ₹3,040 crore, driven by strong sales in key markets. Despite patent disputes affecting Leqselvi's launch, the company continues to invest in its specialty pipeline and reported a consolidated revenue of ₹13,291 crore, reflecting a 9% YoY growth.

Sun Pharma Q2 Results Preview Indicates Strong Growth - 27 Oct, 2024

Sun Pharma is expected to report a 25% YoY increase in net profit and 11.4% YoY revenue growth for Q2FY25, driven by strong domestic sales and specialty products. Analysts anticipate improved gross margins and steady growth in the specialty portfolio.

Sun Pharma to Announce Q2 Results with Focus Areas - 26 Oct, 2024

Sun Pharmaceuticals will announce its financial results for the September quarter, with attention on revenue growth, US formulation business performance, and R&D investments.